Linden Sp. z o.o. sp.k.

The centre is conducting studies on cardiovascular diseases such as acute myocardial infarction, heart failure and hypertension, aiming to test new therapies that lower the risk of major cardiac events.

• Acute myocardial infarction
• Heart failure with preserved ejection fraction
• Hypertension
• Atherosclerotic cardiovascular disease
• Elevated lipoprotein(a)

Trials at Linden Sp. z o.o. sp.k. focus on reducing cardiovascular mortality, improving functional capacity and evaluating the safety of novel agents.

Research in neurological disorders includes amyotrophic lateral sclerosis, Parkinson's disease and various headache conditions, with objectives to slow disease progression and relieve symptoms.

• Amyotrophic Lateral Sclerosis (ALS)
• Parkinson's disease
• Migraine (episodic and chronic)
• Traumatic brain injury (subacute moderate to severe)
• Insomnia disorder
• Narcolepsy with cataplexy (type 1)

The studies aim to evaluate disease‑modifying agents, novel pain‑relief strategies and sleep‑improving treatments while monitoring long‑term safety.

The site is exploring therapies for metabolic and nutritional diseases such as obesity, type 2 diabetes and related bone health concerns, seeking to improve metabolic control and weight outcomes.

• Overweight and obesity with type 2 diabetes
• Type 2 diabetes mellitus
• Weight reduction interventions
• Bone mineral density in women using hormonal contraception
• Metabolic syndrome components

Trials evaluate agents like oral semaglutide and CagriSema to enhance glycaemic control, promote weight loss and support skeletal health.

Investigations into respiratory and allergic conditions target asthma, allergic rhinoconjunctivitis and interstitial lung disease, with the goal of improving lung function and symptom relief.

• Asthma
• Allergic rhinoconjunctivitis caused by pollen exposure
• Interstitial lung disease (ILD)
• Chronic obstructive pulmonary disease (COPD) (exploratory)

Studies compare inhaled corticosteroid/long‑acting β‑agonist combinations and pollen‑extract immunotherapies to standard care, assessing efficacy and safety.

The centre focuses on musculoskeletal and pain conditions, evaluating novel analgesics and spasticity treatments to enhance patient quality of life.

• Chronic non‑specific low back pain
• Post‑surgical neuropathic pain
• Upper‑limb spasticity after stroke or TBI
• Musculoskeletal physiological phenomena
• Osteoarthritis (investigational)

Research aims to determine optimal dosing of pain‑relieving agents, evaluate botulinum toxin for spasticity and assess functional outcomes.

Studies address immune‑mediated and autoimmune diseases such as systemic sclerosis and chronic inflammatory demyelinating polyneuropathy, testing biologics for disease control.

• Systemic sclerosis (limited and diffuse cutaneous subsets)
• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• General autoimmune diseases
• Skin and connective tissue diseases
• Immune system disorders

The trials compare agents like anifrolumab and other targeted therapies to standard treatments, focusing on safety, efficacy and patient‑reported outcomes.